A review of 185 patients who developed recurrent intra-abdominal cancer has been undertaken to compare the results after emergency (41 patients) and elective (144 patients) surgery. The overall postoperative mortality was 19% and morbidity 45%. The mean survival was 13 +/- 20 months, median 7 months and cumulative 5-year survival 5%. The postoperative relief of symptoms was 7 +/- 18 months. A statistically significantly poorer prognosis was observed in emergency patients when compared with those operated on electively. Postoperative mortality and morbidity rates after emergency operations were 41% and 68% and after elective surgery 13% and 39%. The mean survival in the emergency group, 5 +/- 10 months, was significantly shorter than in the elective group, 17 +/- 22 months. The postoperative relief of symptoms for emergency patients was 2 +/- 3 months and for elective patients 10 +/- 22 months. Postoperative sepsis was the most common complication in the emergency group and it caused death in 9 of the 10 cases. Formation of intestinal fistula and early obstruction were the most frequent complications in the elective group. Emergency resections and bypass procedures carried the lowest risk of mortality, 33% and 11%, when compared with enterostomy and laparotomy, which were accompanied by a mortality of 61% and 50%. It is concluded that resective surgery has the best chance to improve survival in emergency surgery for recurrent cancer, although it is associated with a high risk of morbidity and mortality and a disappointingly short relief of symptoms. If resection is not feasible, the possibility of creating a bypass should be considered.
Download full-text PDF |
Source |
---|
Alzheimers Dement
December 2024
University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Background: Pharmacoepidemiologic studies assessing drug effectiveness for Alzheimer's disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real-world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.
Method: We developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011-2013; mean age 75.
Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.
View Article and Find Full Text PDFBackground: Lecanemab is a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils. In two clinical studies (phase 2, NCT01767311 and phase 3 ClarityAD, NCT03887455) in early Alzheimer's disease, lecanemab substantially reduced amyloid PET and significantly slowed clinical decline on multiple measures of cognition and function, including CDR-SB at 18 months. Models describing the change in amyloid PET and CDR-SB in response to lecanemab treatment were used to explore the impact of changing from the initial dosage regimen (10 mg/kg every 2 weeks [Q2W]) to a less intensive maintenance dosing regimen (10 mg/kg every 4 weeks [Q4W]) on clinical efficacy, and to explore the optimal duration of the initial dosing regimen.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.
Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.
Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.
Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!